SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of ...
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced a strategic transaction to exclusively ...
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of ...
Presentations Include Data from More than Thirty NanoString-Related Abstracts Including Five Using the GeoMx Digital Spatial Profiler “Immunotherapy represents one of the most exciting fields for ...
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of a Single Cell Gene ...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently endorse routine ...
NanoString plans to use its IPO proceeds to commercialize the nCounter analyzer and Prosigna test.--Courtesy of NanoString Investor excitement over NanoString's breast cancer diagnostic may not be as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback